Skip to content

Functional and Neurochemical Brain Changes in First-episode Bipolar Mania

Functional and Neurochemical Brain Changes in First-episode Bipolar Mania Following Successful Treatment With Lithium or Quetiapine

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00609193
Enrollment
81
Registered
2008-02-06
Start date
2008-01-31
Completion date
2015-07-31
Last updated
2015-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Disorder

Brief summary

The purpose of this study is to use magnetic resonance imaging (MRI) to examine brain structure, function and chemistry in people with bipolar disorder who are being treated with either quetiapine or lithium. Both of these medicines are FDA-approved to treat mania in adults and lithium is also FDA approved in children; quetiapine is commonly used in children with mania, but is not FDA approved for this indication in this age group.

Interventions

DRUGlithium

standard clinical care

DRUGquetiapine

standard clinical care

Sponsors

National Institutes of Health (NIH)
CollaboratorNIH
University of Cincinnati
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
12 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

- First-episode manic bipolar patients (N=100; 15-20 patients/year): 1. Patients meet DSM-IV criteria for type I bipolar disorder, manic or mixed. 2. Patients have an index Young Mania Rating Scale (YMRS)70 total score \>20. 3. Patients have \<3 months of lifetime anti-manic or anti-depressant medication exposure, including no active psychotropic medication in the one weeks prior to the index admission. Importantly, patients will NOT be taken off medications for this study; this criterion is to exclude subjects receiving active treatment at the time of admission to support the 'first-episode' criterion. 4. Patients have no more than two prior episodes of major depression. 5. Patients are between 12 and 35 years old; subjects \< 18 yrs old have a Tanner greater than or equal to 4

Exclusion criteria

All subjects will be excluded from participation for the following reasons. 1. Any chemical use disorder within 3 months. 2. Any medical or neurological disorder that could influence fMRI and MRS results. 3. A history of mental retardation or an estimated IQ total score \<85. 4. An MRI scan is contraindicated in the subject. 5. The patient cannot attend follow-up visits. 6. A positive urine pregnancy test (in women).

Design outcomes

Primary

MeasureTime frame
The purpose of this study is to use magnetic resonance imaging (MRI) to examine brain structure, function and chemistry in people with bipolar disorder who are being treated with either quetiapine or lithium.8 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026